Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9827867 | 0.88 | — | — | |
| SCHEMBL151744 | 0.74 | TSHR (0.41) | SHBG | |
| SCHEMBL9815822 | 0.74 | TSHR (0.41) | SHBG | |
| SCHEMBL16767910 | 0.73 | SHBG (0.36) | SHBG | |
| SCHEMBL10031072 | 0.73 | SHBG (0.36) | SHBG | |
| SCHEMBL14650544 | 0.71 | CA1 (0.35) | — | |
| SCHEMBL7191308 | 0.71 | LMNA (0.32) | SHBG | |
| SCHEMBL21668241 | 0.71 | — | — | |
| SCHEMBL22180925 | 0.71 | NCF1 (0.46) | — | |
| SCHEMBL18096501 | 0.70 | TSHR (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236047-B2 | Combination of isoindolinone derivatives with SGI-110 | ASTEX THERAPEUTICS LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-20210276984-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
| US-10981898-B2 | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-20 | — | — | US | disclosed |
| US-20200247789-A2 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUCTICS LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| US-20200207711-A1 | COMBINATION OF ISOINDOLINONE DERIVATIVES WITH SGI-110 | ASTEX THERAPEUTICS LIMITED (GB) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236047-B2 | Combination of isoindolinone derivatives with SGI-110 | SGK3, SGK2, GDI2 | SHBG 486/4885 |
| US-10981898-B2 | Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity | TP53, MDM2, TP53BP1 | SHBG 2226/4885 |
| US-20200207711-A1 | COMBINATION OF ISOINDOLINONE DERIVATIVES WITH SGI-110 | SGK3, SGK2, GDI2 | SHBG 486/4885 |
| US-20210276984-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | SHBG 2226/4885 |
| US-20200247789-A2 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | SHBG 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.